Results 121 to 130 of about 495,016 (275)

Disorders of sex development (DSD): an overview of recent scientific advances [PDF]

, 2014
Developments in biotechnology have radically altered clinical and research themes in the small field of disorders of sex development, as in other rare medical conditions. In the age of genetics, an increasing number of DSDs have been identified. Aided by
Conway, GS
core  

Efficacy and Safety of ABBV‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective Despite the availability of biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks.
Frank Buttgereit, Atul Singhal, Alan Kivitz, Edit Drescher, Yoshinori Taniguchi, Rosalía Martínez Pérez, Jaclyn Anderson, Ronilda D'Cunha, Weihan Zhao, Nicholas DeVogel, Julie Parmentier, Romy Christmann, Dilek Arikan, Howard Amital   +13 more
wiley   +1 more source

Clinical Paediatric Endocrinology [PDF]

, 1972
William Hamilton
openalex   +1 more source

Book Review: Fundamentals of Clinical Endocrinology [PDF]

, 1974
Christopher R.W. Edwards
openalex   +1 more source

Prognostic value of lupus anticoagulant and anti‐β2 glycoprotein I antibody in adverse pregnancy outcomes.

Arthritis &Rheumatology, Accepted Article.
Objective International criteria for antiphospholipid syndrome (APS) include lupus anticoagulant (LA), anticardiolipin (aCL) immunoglobulin (Ig) G and IgM, and anti‐β2‐glycoprotein I (β2GPI) IgG and IgM. However, evidence supporting their prognostic value or treatment efficacy in improving live birth rates is limited.
Megumi Nonobe, Takahiro Otani, Hiroyuki Yoshihara, Shinobu Goto, Tamao Kitaori, Naomi Nishikawa, Yuichiro Fujieda, Tatsuya Atsumi, Mayumi Sugiura‐Ogasawara   +8 more
wiley   +1 more source

The fate of thiopurine metabolites after switching to low‐dose thiopurine with allopurinol or thioguanine in IBD patients: A retrospective analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Shunting (hypermethylating) thiopurine metabolism, characterized by excessive 6‐MMPR production and (sub)therapeutic 6‐TGN levels, poses a significant challenge in the treatment of inflammatory bowel disease (IBD). This study evaluates the metabolic outcomes of switching to low‐dose thiopurine with allopurinol (LDTA) or thioguanine (TG) in IBD ...
Ahmed B. Bayoumy, Hedwig M. A. D'Agnolo, Nanne K. H. de Boer, Chris J. J. Mulder, Luc J. J. Derijks   +4 more
wiley   +1 more source

Endocrinology: Clinical significance of invisible or partially visible luteinizing hormone [PDF]

, 1994
Rémy C. Martin-Du-Pan, Martin Hořák, P. Bischof   +2 more
openalex   +1 more source

Probability of pharmacokinetic/pharmacodynamic target attainment for different piperacillin/tazobactam dosing regimens in renally impaired patients in a non‐intensive care unit setting

British Journal of Clinical Pharmacology, EarlyView.
Aims To optimize antibiotic therapy for pathogens classified as susceptible, increased exposure (I), an increased exposure of piperacillin/tazobactam (PTZ) is required. However, dosing recommendations are currently only available for patients with normal renal function.
Emma Dohmann, Stefan Hagel, Max Kurlbaum, Paul Schellong, Oliver Scherf‐Clavel, Güzin Surat   +5 more
wiley   +1 more source

Steroid Metabolism and Clinical Endocrinology

, 1952
Ian F. Sommerville
openalex   +1 more source

Book Review: Clinical Endocrinology and Metabolism—Growth Factors in Endocrinology [PDF]

, 1992
B T Rudd
openalex   +1 more source